Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Cyclosorus terminans Extract Ameliorates Insulin Resistance and Non-Alcoholic Fatty Liver Disease (NAFLD) in High-Fat Diet (HFD)-Induced Obese Rats

Songtrai S., Pratchayasakul W., Arunsak B., Chunchai T., Kongkaew A., Chattipakorn N.

Animal Study on Type 2 Diabetes, Chronic Inflammation, published in Nutrients (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Nutrients (2022)
Reported sample size
—
Source database
Europe PMC
PMID
36432581
PMCID
PMC9693870
DOI
10.3390/nu14224895
Citations
7

Abstract (original English)

Interruptins A and B exhibited anti-diabetic, anti-inflammatory, and anti-oxidative effects. This study aimed to investigate the therapeutic ability of extract enriched by interruptins A and B (EEI) from an edible fern Cyclosorus terminans on insulin resistance and non-alcoholic fatty liver disease (NAFLD) in a high-fat diet (HFD)-induced obese rats and elucidate their possible mechanisms. HFD-induced obese rats were treated with EEI for 2 weeks. Real-time polymerase chain reaction (PCR) was used to examine the molecular basis. We found that EEI supplementation significantly attenuated body and liver weight gain, glucose intolerance, and insulin resistance. Concurrently, EEI increased liver and soleus muscle glycogen storage and serum high-density lipoprotein (HDL) levels. EEI also attenuated NAFLD, as indicated by improving liver function. These effects were associated with enhanced expression of insulin signaling genes ( Slc2a2, Slc2a4, Irs1 and Irs2 ) along with diminished expression of inflammatory genes ( Il6 and Tnf ). Furthermore, EEI led to the suppression of lipogenesis genes, Srebf1 and Fasn , together with an increase in fatty acid oxidation genes, Ppara and Cpt2 , in the liver. These findings suggest that EEI could ameliorate HFD-induced insulin resistance and NAFLD via improving insulin signaling pathways, inflammatory response, lipogenesis, and fatty acid oxidatio

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsRatsInsulin ResistanceObesityInsulinFatty AcidsAnti-Inflammatory AgentsDiet, High-FatNon-alcoholic Fatty Liver DiseaseTracheophyta

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research